ESC Premium Access

A phase 3 study in an enriched population of pulmonary arterial hypertension patients with long term oxygen use demonstrating improved exercise tolerance with use of ambulatory inhaled nitric oxide

Congress Session

About the speaker

Professor Harrison Farber

Adelphi Communications, Bollington (United Kingdom of Great Britain & Northern Ireland)
0 follower

9 more presentations in this session

Subcutaneous treprostinil for the treatment of non-operable chronic thromboembolic pulmonary hypertension: a randomized, controlled trial (CTREPH)

Speaker: Doctor R. Sadushi-Kolici (Vienna, AT)

Thumbnail

Comparative receptor pharmacology, pre-clinical efficacy and pharmacokinetics of a novel, next-generation prostacyclin receptor agonist, ralinepag (APD811), in humans and rats

Speaker: Doctor J. Adams (San Diego, US)

Thumbnail

Cardiac magnetic resonance characterization of maladaptive right ventricular hypertrophy in chronic pulmonary hypertension.

Speaker: Doctor I. Garcia Lunar (Madrid, ES)

Thumbnail

APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery

Speaker: Doctor J. Patel (London, GB)

Thumbnail

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease

Speaker: Miss B. Girerd (Clamart, FR)

Thumbnail

Access the full session

Progress in the management of pulmonary hypertension

Speakers: Professor H. Farber, Doctor R. Sadushi-Kolici, Doctor J. Adams, Doctor I. Garcia Lunar, Doctor J. Patel...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk